PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.
PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.
The user experienced temple recession, shedding, and acne while on 0.5mg dutasteride, 1.25mg finasteride every other day, and 5mg oral minoxidil daily. They are considering switching treatments due to worsening symptoms and are contemplating using a topical anti-androgen like RU58841.
The user switched from 1mg finasteride to 0.5mg dutasteride 10 months ago but noticed more hair loss and questions the effectiveness of the dutasteride purchased from costplusdrugs. They are concerned whether the product is genuine or if they are simply not responding to the treatment.
The user reported noticeable hair regrowth after using dutasteride 0.5 mg, oral minoxidil 2.5 mg daily, and ketoconazole shampoo weekly for six months. They are considering adding RU58841 for further improvement.
The user has been using a combination of oral finasteride, oral dutasteride, topical and oral minoxidil, microneedling, and keto shampoo for hair loss, experiencing significant shedding recently. Suggestions include simplifying the regimen by dropping finasteride and topical minoxidil, and possibly adding RU58841, while others advise maintaining the current approach for consistent results.
The user experienced severe scalp issues and hair loss after using ketoconazole shampoo, which worsened despite various treatments. They seek advice on restoring scalp health, suspecting an allergic reaction or imbalance caused by the shampoo.
A user's 8-month progress using dutasteride, oral minoxidil, and 2 weeks of RU58841 to treat hair loss. The user is looking for feedback from others on their progress and experiences.
Using finasteride and peptides, including GHK-Cu, improved hair thickness and regrowth. The user also used a KLOW blend and CJC/IPA for better sleep and recovery.
Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.
A user's experience with Dutasteride causing rapid hair loss and temple recession over 3 weeks, with other users offering advice about the potential causes of this.
The conversation is about a user's one-year hair loss treatment using dutasteride, oral and topical minoxidil, ketoconazole, tretinoin, and PRP. Users discuss treatment effectiveness, potential issues with diffuse thinning, and sourcing affordable treatments.
The user is using 0.1% dutasteride, 1% minoxidil with 2% procapil and 0.005% caffeine in the morning, and 1% minoxidil with 2% procapil and 0.01% tretinoin at night. They are concerned about the solution vehicle's effectiveness in preventing systemic absorption and ensuring the products stay around the hair follicles.
A user stopped finasteride after 15 years due to severe side effects, which improved after quitting. They maintained most of their hair and are considering alternatives like topical treatments or RU58841.
The user is experiencing increased hair shedding and is considering switching from a topical solution containing minoxidil, finasteride, and tretinoin to oral minoxidil while continuing oral dutasteride. They are seeking advice on whether to make this switch or wait for the shedding to stabilize, and are concerned about potential side effects of oral minoxidil.
User shared 2-year progress with Dutasteride, 5mg oral minoxidil, and 7 months of RU58841 for hair growth. RU58841 was most effective, stopping itching and promoting significant growth.
The conversation is about a user experiencing hair shedding after using a brand of RU58841, questioning its effectiveness and safety. Concerns are raised about RU58841 being an abandoned research chemical and the use of heavy oils like castor and argan oil potentially affecting absorption.
The conversation discusses arranging an interview with the developers of RU58841 to clarify its safety and reasons for halted research, with some users expressing concerns about potential risks and others citing financial reasons for the discontinuation of studies. Specific treatments mentioned include RU58841, minoxidil, and finasteride.
The conclusion of the conversation is that the user, General-Switch-5722, has been using finasteride and minoxidil for over 2 years but is still experiencing hair loss. They are considering adding a low dose of RU58841 or topical dutasteride as potential treatments. Other users in the conversation have suggested switching to dutasteride or using oral minoxidil.
Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.
A user has been taking Propecia (finasteride) for 7 months and uses topical minoxidil, but is considering switching to dutasteride due to ongoing hair shedding. Another person suggests that 7 months is not enough time to decide on switching medications.
The user has been using topical finasteride (0.1%) and minoxidil (5%) for over 8 months, experiencing significant hair shedding and loss of density, and is considering switching to topical dutasteride. They are hesitant to switch due to potential shedding but plan to wait until the 12-month mark before making a decision.
A user who has tried multiple treatments for hair loss, including oral and topical finasteride and liposomal finasteride, but experienced severe side effects in each case; the user is considering trying RU58841 or aromatise inhibitors as alternatives.
Kintor's Phase II U.S. trials for pyrilutamide and the process of pharmaceutical drugs coming to market, with a reply from someone who has just ordered 500mg of Pyrilutamide to start their own phase trials.
A user plans to create a DIY topical treatment for hair loss using Rapamycin, possibly combined with alpha-ketoglutaric acid (a-KG). They discuss the concentration and formulation process for Rapamycin, considering safety and skin penetration, and intend to apply it every other day to the scalp.
The conversation discusses the HMI-115 trial for hair loss, which was expected to end around July 2023 due to a late participant. Participants also mention Minoxidil, finasteride, and RU58841 as treatments.
Clascoterone 5% shows promising hair growth results but is criticized for high cost and unclear effectiveness compared to other treatments like finasteride. Glenmark is testing a combination of Clascoterone 7.5% and Minoxidil 5% in India.
The conversation discusses DIY cosmetic procedures like PRP, mesotherapy, and micro-needling, with some users experimenting with Minoxidil, finasteride, and RU58841 for hair loss. It highlights a community of mostly older women performing these treatments themselves.
The conversation discusses using minoxidil, finasteride, spironolactone, and RU58841 for hair loss treatment. Users share experiences with these treatments, noting side effects and varying effectiveness.
The user is using dutasteride, finasteride, and RU58841 for hair loss but is allergic to minoxidil. Suggestions include dropping finasteride, increasing dutasteride dosage, and considering alternatives like microneedling, laser treatments, scalp massage, and supplements.